Overview

IVIG vs SCIG in CIDP

Status:
Recruiting
Trial end date:
2024-10-18
Target enrollment:
Participant gender:
Summary
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
Phase:
Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Treatments:
Antibodies
gamma-Globulins
Immunoglobulin G
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin